Go Back

Content Compliance, Simplified

Vodori is on a mission to transform lives by bringing regulated products to market faster. We help life science teams stay compliant and improve the material review process with intuitive, tailored software and peerless customer support. Subscribe for best practices and insights on the material review process, regulatory compliance, and team collaboration.

Content Compliance, Simplified

Software & Technology

Amend & Progress: Exploring Four Perspectives in 2024 and Beyond

Annalise Ludtke
March 28, 2024
2024 perspectives
Amend & Progress
Annalise Ludtke
life sciences
+more

 

In a dynamic exchange on the Amend & Progress podcast by Vodori, Annalise Ludtke explores four perspectives in 2024 that will help bring effective content to the market now and beyond. With the participation of Vodori’s CEO and Co-Founder, Scott Rovegno, the conversation unveils insights on macro-level topics crucial to the organization’s strategic direction.

This episode unpacks Vodori’s forward-thinking on essential themes: content strategy, AI, best practices, and technology optionality. Through a rich dialogue between Ludtke and Rovegno, viewers gain a comprehensive view of Vodori’s philosophy, bolstered by a commitment to innovation, customer-centricity, and the strategic employment of technology. From enhancing content efficacy beyond mere volume to leveraging AI for material review, Ludtke and Rovegno offer actionable insights and underscore the importance of adaptability and trust in the rapidly evolving digital landscape.

The heart of this discussion acknowledges the human element in digital processes, a principle that Vodori staunchly upholds across its operations and product development strategies. The conversation also highlights the significance of best practices in fostering effective collaboration and the role of technology optionality in ensuring agility and competitive advantage in the marketplace. The four perspectives in 2024 explored in this episode provide a roadmap to success for today, tomorrow, and the future.

 

Recent Episodes

vitro
View episode

Analyzing the Suppressive TME in In Vitro Based Assays

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

cancer
View episode

Targeting T Cells Within the Cancer Immunity Cycle

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

cancer Immunity cycle
View episode

Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Launch Your Branded Show Today

Engage your audience with original, industry-specific content.

Book a Demo Talk to an Expert